Department of Oncology, University of Sheffield, Sheffield, UK,
Langenbecks Arch Surg. 2014 Feb;399(2):245-51. doi: 10.1007/s00423-014-1168-8. Epub 2014 Jan 21.
Sentinel node biopsy (SNB) may identify lymph node metastases in patients with papillary thyroid cancer (PTC), enabling selective application of central node dissection (CND). The aim of this study was to assess the feasibility of implementing SNB in patients undergoing thyroidectomy for a cytologically indeterminate/suspicious/malignant thyroid nodule and to determine the potential improvement in clinical outcomes and the costs associated with the SNB technique.
The treatment strategies and clinical and pathological outcomes of two retrospective cohorts of patients who underwent preoperative thyroid FNA over a 5-year period in two different centres were studied. The potential for implementing the SNB technique and the benefits and costs associated with implementation were estimated.
In centre 1, in 819 adult patients who had thyroid fine-needle aspiration cytology, the final cytology was indeterminate, suspicious and diagnostic of malignancy in 113, 29 and 28 patients, respectively. One hundred eight patients were 'suitable' for SNB. Twenty-three of these patients had PTC, six of whom underwent CND. Of these six patients, node metastasis was absent in five--the cohort in whom prophylactic CND may have been avoided consequent to a negative 'sentinel node' biopsy. Morbidity attributable to CND may have been avoided in up to four patients over a 5-year period. Costs associated with implementation of SNB outweighed any potential savings. Analysis of 491 patients in centre 2 confirmed that the benefit of SNB in PTC was similarly limited; morbidity attributable to CND may have been avoided in up to seven patients over a 5-year period.
Even under ideal conditions (assuming 100 % node identification rate and 0 % false negative rate), the potential short- to medium-term benefit of sentinel node biopsy in patients with thyroid cancer in centres implementing a policy of selective or routine prophylactic CND is low.
前哨淋巴结活检(SNB)可识别甲状腺乳头状癌(PTC)患者的淋巴结转移,从而选择性地应用中央淋巴结清扫术(CND)。本研究旨在评估在因细胞学不确定/可疑/恶性甲状腺结节而行甲状腺切除术的患者中实施 SNB 的可行性,并确定 SNB 技术相关的临床结局和成本的潜在改善。
研究了两个不同中心在 5 年内对接受术前甲状腺细针穿刺抽吸活检的两个回顾性队列的治疗策略及临床和病理结局。估计了实施 SNB 技术的潜力以及实施该技术的获益和成本。
在中心 1,对 819 例进行甲状腺细针抽吸细胞学检查的成年患者,最终细胞学检查结果分别为 113 例不确定、29 例可疑和 28 例恶性。108 例患者“适合”SNB。这 108 例患者中有 23 例患有 PTC,其中 6 例行 CND。这 6 例患者中,5 例无淋巴结转移——这部分患者可能由于“前哨淋巴结”活检阴性而避免了预防性 CND。在 5 年内,可能有多达 4 例患者避免了与 CND 相关的并发症。SNB 实施的相关成本超过了任何潜在的节省。对中心 2 的 491 例患者的分析证实,SNB 在 PTC 中的获益也同样有限;在 5 年内,可能有多达 7 例患者避免了与 CND 相关的并发症。
即使在理想条件下(假设 100%的淋巴结识别率和 0%的假阴性率),在实施选择性或常规预防性 CND 政策的中心中,甲状腺癌患者 SNB 的短期至中期获益也很低。